Hutchmed (HCM) announced that Takeda (TAK) has submitted a new drug application, or NDA, to the Ministry of Health, Labour and Welfare, or MHLW, in Japan for the approval of fruquintinib for the treatment of adult patients with previously treated metastatic colorectal cancer, or CRC. Fruquintinib is a selective inhibitor of vascular endothelial growth factor receptors -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis. CRC has the highest incidence and second highest mortality rate among both men and women in Japan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCM:
- HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
- HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
- HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
- HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
- Hutchmed receives breakthrough therapy designation in China for Savolitinib
